Modality
ASO
MOA
TNFi
Target
Menin
Pathway
T-cell
Endometrial CaAS
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
Jul 2021
→ Jan 2030
Phase 2Current
NCT05167859
578 pts·AS
2021-07→2030-01·Completed
NCT04730509
946 pts·Endometrial Ca
2021-09→TBD·Not yet recruiting
1,524 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-133.8y awayPh3 Readout· AS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-01-13 · 3.8y away
AS
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05167859 | Phase 2/3 | AS | Completed | 578 | ACR20 |
| NCT04730509 | Phase 2/3 | Endometrial Ca | Not yet recr... | 946 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Cevimavacamten | Denali | NDA/BLA | Menin |